The global CNS drug discovery market is projected to grow significantly, from USD 9.80 billion in 2025 to USD 27.55 billion by 2035, with a compound annual growth rate (CAGR) of 10.90% from 2026 to 2035. Key drivers include the rising prevalence of CNS disorders, increased integration of AI and ML in drug discovery, and enhanced government support for clinical trials. North America dominated the market in 2025 with a 43% share, while Asia-Pacific is expected to see the fastest growth at a CAGR of 14%.
Innovations such as gene therapies and biomarker-based discoveries are paving the way for advancements in the sector. Alzheimer’s disease treatment leads in market share and expected growth rates, highlighting a crucial need for effective therapies. Overall, technological advancements and personalized medicine approaches present vast opportunities, despite challenges like clinical setbacks and difficulties in crossing the blood-brain barrier.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.precedenceresearch.com/cns-drug-discovery-market
